TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22350679

Group type: EXPERIMENTAL
Intervention: 100 mcg of HFA‐BDP twice daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 400 mcg of HFA‐BDP twice daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oral prednisolone (25 mg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 20212073

Group type: COMPARATOR
Intervention: Diet intervention
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: High-dose niacin 2000 mg plus lovastatin 40 mg
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Low-dose niacin 1000 mg plus lovastatin 40 mg
Number of subjects: 385
Study: 17707010

Group type: EXPERIMENTAL
Intervention: Desmopressin and oxybutynin
Number of subjects: 54

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 54
Study: 16375657

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (GbE) at daily doses of 120 mg
Number of subjects: 513

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (GbE) at daily doses of 240 mg
Number of subjects: 513

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 513
Study: 12195242

Group type: EXPERIMENTAL
Intervention: Epitalon (Ala‐Glu‐Asp‐Gly)
Number of subjects: 0
Study: 9626341

Group type: EXPERIMENTAL
Intervention: 4-HPR
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control
Number of subjects: 39
Study: 8566919

Group type: EXPERIMENTAL
Intervention: Head space-solid phase microextraction and gas chromatography-mass spectrometry/chemical ionization selected ion monitoring
Number of subjects: 0
Study: 2669441

Group type: EXPERIMENTAL
Intervention: 300 mg moclobemide
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 150 mg clomipramine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 1102484

Group type: EXPERIMENTAL
Intervention: Ara‐A ointment
Number of subjects: 52

Group type: COMPARATOR
Intervention: IDU ointment
Number of subjects: 52
Study: 31880826

Group type: EXPERIMENTAL
Intervention: LY3023414
Number of subjects: 28
Study: 31174526

Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice daily with aspirin 81 mg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice daily without aspirin
Number of subjects: 70

Group type: COMPARATOR
Intervention: Aspirin 81 mg
Number of subjects: 70
Study: 28946020

Group type: EXPERIMENTAL
Intervention: Power posing
Number of subjects: 73

Group type: COMPARATOR
Intervention: Submissive posing
Number of subjects: 73

Group type: COMPARATOR
Intervention: Rest (no posing)
Number of subjects: 73
Study: 25727679

Group type: EXPERIMENTAL
Intervention: Child treated
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Child treated and parent participates in the course
Number of subjects: 55

Group type: COMPARATOR
Intervention: Wait-list for 12 weeks
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Comorbid disorders
Number of subjects: 55
Study: 23713812

Group type: COMPARATOR
Intervention: IL‐1RN2/2 genotype
Number of subjects: 140

Group type: COMPARATOR
Intervention: IL‐1RN1/2 genotype
Number of subjects: 140

Group type: COMPARATOR
Intervention: Allele 2 of IL‐1RN gene
Number of subjects: 140

Group type: COMPARATOR
Intervention: C-reactive protein (CRP) levels
Number of subjects: 140
Study: 21550027

Group type: EXPERIMENTAL
Intervention: Amolimogene (microparticle encapsulated pDNA vaccine)
Number of subjects: 21
Study: 19301724

Group type: COMPARATOR
Intervention: Continuous epidural infusion (CEI) with 0.125% levobupivacaine and morphine 0.0125 mg/ml (4 ml/hr)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block (CFNB) with 0.125% levobupivacaine (8 ml/hr)
Number of subjects: 61
Study: 17201996

Group type: EXPERIMENTAL
Intervention: R,S‐citalopram (20 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: S‐citalopram (10 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: R,S‐citalopram
Number of subjects: 8

Group type: COMPARATOR
Intervention: S‐citalopram
Number of subjects: 8
Study: 15467526

Group type: COMPARATOR
Intervention: beta2 sympathomimetics
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: glyceryl trinitrate (GTN)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: both groups
Number of subjects: 238
Study: 15170981

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) and l-leucovorin (l-LV) given monthly (arm A)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) and l-leucovorin (l-LV) given every 2 months (arm B)
Number of subjects: 54
Study: 11408900

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (25 mg) injected once per week for 5 weeks
Number of subjects: 78

Group type: COMPARATOR
Intervention: Dexamethasone (2 mg) injected once per week for 5 weeks
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Both groups (SH and steroid)
Number of subjects: 78
Study: 9412547

Group type: EXPERIMENTAL
Intervention: Zafirlukast (20 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8500235

Group type: EXPERIMENTAL
Intervention: Hydralazine/isosorbide dinitrate (H-I)
Number of subjects: 1446

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 1446

Group type: COMPARATOR
Intervention: Placebo and prazosin
Number of subjects: 1446

Group type: EXPERIMENTAL
Intervention: H-I and Enalapril
Number of subjects: 1446

Group type: EXPERIMENTAL
Intervention: Change in LVEF (> 5) from baseline
Number of subjects: 1446
Study: 2892862

Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Prazosin administration
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 29107439

Group type: EXPERIMENTAL
Intervention: Integrated Care (IC)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Low Extremities Exercise (LEE)
Number of subjects: 110
Study: 26733057

Group type: EXPERIMENTAL
Intervention: Ovaleap® (150 IU/day for 5 days, then dose-adjusted up to 450 IU/day)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Gonal-f® (150 IU/day for 5 days, then dose-adjusted up to 450 IU/day)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Ovaleap® and Gonal-f®
Number of subjects: 299
Study: 25069431

Group type: EXPERIMENTAL
Intervention: Fluoxetine or tianepine with cognitive-behavioral therapy, supportive therapy, or psychodynamic therapy
Number of subjects: 821

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 821
Study: 24094792

Group type: EXPERIMENTAL
Intervention: INCREASE PA
Number of subjects: 52

Group type: COMPARATOR
Intervention: DECREASE TV
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: INCREASE PA+DECREASE TV
Number of subjects: 52
Study: 21627399

Group type: EXPERIMENTAL
Intervention: Turmeric supplementation (500 mg per capsule, 3 capsules daily for 2 months)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (starch capsules identical in colour and size)
Number of subjects: 40
Study: 18196350

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 9978

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 9978

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 9978

Group type: EXPERIMENTAL
Intervention: Predictors of 1-year mortality
Number of subjects: 9978

Group type: EXPERIMENTAL
Intervention: 30-day follow-up
Number of subjects: 9978
Study: 17019956

Group type: EXPERIMENTAL
Intervention: Infrared laser radiation on the adrenal projection region
Number of subjects: 0
Study: 14582592

Group type: EXPERIMENTAL
Intervention: Calcium aluminate cement (CAC)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Resin composite (RC)
Number of subjects: 57
Study: 10765039

Group type: EXPERIMENTAL
Intervention: Intravenous cefotiam dihydrochloride (CTM) 2 g on induction of anesthesia
Number of subjects: 207

Group type: COMPARATOR
Intervention: Oral cefpodoxime proxetil (CPDX-PR) 100 mg twice daily from day 0 to day 2
Number of subjects: 207
Study: 8685664

Group type: EXPERIMENTAL
Intervention: Pay ($3.40/hour)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Participation in work activity
Number of subjects: 150
Study: 1321542

Group type: EXPERIMENTAL
Intervention: 600 micrograms.kg‐1 rocuronium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1.5 mg.kg‐1 suxamethonium preceded by 10 mg gallamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no muscle relaxant)
Number of subjects: 0
Study: 6376208

Group type: EXPERIMENTAL
Intervention: Chlorthalidone 50 mg/triamterene 50 mg once-daily oral doses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorthalidone 50 mg alone
Number of subjects: 0
Study: 31686529

Group type: EXPERIMENTAL
Intervention: 3D-printed orthosis
Number of subjects: 40

Group type: COMPARATOR
Intervention: low-temperature thermoplastic plate orthosis
Number of subjects: 40
Study: 31810850

Group type: EXPERIMENTAL
Intervention: Vacuum-assisted closure (VAC) therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional bolster dressing (CBD)
Number of subjects: 50
Study: 26559710

Group type: EXPERIMENTAL
Intervention: Increase physical activity (iPA)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Decrease sedentary leisure (dSED)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Daily changes in MVPA
Number of subjects: 204
Study: 25027479

Group type: EXPERIMENTAL
Intervention: Tailored physical activity program performed in a work environment for 9 months
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 68
Study: 23210527

Group type: EXPERIMENTAL
Intervention: 5-week group cognitive-behavioural stress management (CBSM) programme plus standard care
Number of subjects: 355

Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 355
Study: 20645992

Group type: EXPERIMENTAL
Intervention: Infant Behavioural Assessment and Intervention Program (IBAIP)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 176
Study: 19884268

Group type: EXPERIMENTAL
Intervention: Nonpharmacological treatments
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: No funding
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Multicenter RCT
Number of subjects: 196
Study: 17572579

Group type: EXPERIMENTAL
Intervention: Evolence30 (30 mg/ml)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Zyplast (bovine cross-linked collagen)
Number of subjects: 12
Study: 15194014

Group type: EXPERIMENTAL
Intervention: tenecteplase (TNK‐t‐PA)
Number of subjects: 266

Group type: COMPARATOR
Intervention: alteplase
Number of subjects: 266
Study: 12137881

Group type: EXPERIMENTAL
Intervention: Laparoscopic ovarian diathermy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gonadotropin therapy (three cycles of urinary or recombinant gonadotropins)
Number of subjects: 0
Study: 10981089

Group type: EXPERIMENTAL
Intervention: Various classes of blood pressure-lowering agents
Number of subjects: 270000

Group type: EXPERIMENTAL
Intervention: Systematic overviews and meta-analyses of major ongoing trials
Number of subjects: 270000
Study: 7789479

Group type: EXPERIMENTAL
Intervention: Device No. 1
Number of subjects: 13

Group type: COMPARATOR
Intervention: Technician effects
Number of subjects: 13

Group type: COMPARATOR
Intervention: Team effects
Number of subjects: 13

Group type: COMPARATOR
Intervention: Device effects
Number of subjects: 13
Study: 2206033

Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg once a day with the morning meal (qam)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg once a day with the evening meal (qpm)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Lovastatin 80 mg qpm
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg twice daily
Number of subjects: 290

Group type: COMPARATOR
Intervention: Probucol 500 mg twice daily
Number of subjects: 290
Study: 388220

Group type: EXPERIMENTAL
Intervention: Prednisone (alternate-day treatment for at least eight weeks)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 6354552

Group type: EXPERIMENTAL
Intervention: Dorsal penile nerve block (DPNB) with lidocaine
Number of subjects: 31

Group type: COMPARATOR
Intervention: Dorsal penile nerve block (DPNB) with saline
Number of subjects: 31

Group type: COMPARATOR
Intervention: Circumcision without DPNB
Number of subjects: 31
Study: 30055852

Group type: EXPERIMENTAL
Intervention: 17-item Hamilton Depression Rating Scale (HAM-D17)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: 6-item Hamilton Depression Rating Scale (HAM-D6)
Number of subjects: 237
Study: 29411238

Group type: EXPERIMENTAL
Intervention: Home hospital care (nurse and physician home visits, intravenous medications, continuous monitoring, video communication, point‐of‐care testing)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Home hospital care
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 20
Study: 27475700

Group type: EXPERIMENTAL
Intervention: Topical gel containing chitosan, 0.2% chlorhexidine, allantoin and dexpanthenol applied 10 ml three times a day for 10 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no gel applied)
Number of subjects: 50
Study: 24608624

Group type: EXPERIMENTAL
Intervention: Oral valacyclovir for 1 week
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 22499565

Group type: EXPERIMENTAL
Intervention: Elongated start
Number of subjects: 9

Group type: COMPARATOR
Intervention: Bunched start
Number of subjects: 9

Group type: COMPARATOR
Intervention: Medium start
Number of subjects: 9
Study: 20028967

Group type: EXPERIMENTAL
Intervention: Aerobic training for 10 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Obese controls (n = 12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Endurance-trained athletes (n = 15)
Number of subjects: 24
Study: 18806028

Group type: EXPERIMENTAL
Intervention: Closed-loop control system for propofol administration
Number of subjects: 40

Group type: COMPARATOR
Intervention: Manual control group (anesthesiologist titrated propofol)
Number of subjects: 40
Study: 15577823

Group type: EXPERIMENTAL
Intervention: Tacrolimus (0.1 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 11379646

Group type: EXPERIMENTAL
Intervention: Instillation of local anesthetic (Group I)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Injection of local anesthetic (Group II)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous opioid (Group III)
Number of subjects: 60
Study: 9249783

Group type: EXPERIMENTAL
Intervention: Nitrendipine (2 x 5 mg daily for normotensive patients; 2 x 10 mg to 2 x 20 mg daily for hypertensive patients)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8491391

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate 480 mg/day plus amoxycillin from days 1 to 7 and tinidazole from days 8 to 14
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sucralphate 4 g/day
Number of subjects: 32
Study: 2891631

Group type: EXPERIMENTAL
Intervention: Laparoscopic fulguration of endometriotic implants (Group A)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group (Group B) - implants left intact
Number of subjects: 123
Study: 27677562

Group type: EXPERIMENTAL
Intervention: Urate levels equal to or above the median (5.1 mg/dl)
Number of subjects: 942

Group type: EXPERIMENTAL
Intervention: Highest urate quartile
Number of subjects: 942

Group type: COMPARATOR
Intervention: Lowest urate quartile
Number of subjects: 942
Study: 27110098

Group type: COMPARATOR
Intervention: FDC_EVO5/MET1000
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: FDC_EVO5/MET1000 under fed condition
Number of subjects: 36
Study: 24534779

Group type: EXPERIMENTAL
Intervention: Robotically assisted body weight supported treadmill training (RABWSTT)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Arm cycle ergometry
Number of subjects: 21

Group type: COMPARATOR
Intervention: RABWSTT and arm ergometry
Number of subjects: 21
Study: 22300367

Group type: EXPERIMENTAL
Intervention: Curcumin (2 g)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sulphasalazine (100 µg or 2 g) alone
Number of subjects: 8
Study: 19563327

Group type: EXPERIMENTAL
Intervention: Branemark implant system (two-stage screw type)
Number of subjects: 30
Study: 17993763

Group type: EXPERIMENTAL
Intervention: Trandolapril 0.5 mg qd
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 15889369

Group type: EXPERIMENTAL
Intervention: Posaconazole
Number of subjects: 8
Study: 11605101

Group type: EXPERIMENTAL
Intervention: 0.2 g/kg alcohol
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Alcohol (4.35+/‐0.53 g/kg per week)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Alcohol drink
Number of subjects: 32
Study: 9481347

Group type: EXPERIMENTAL
Intervention: Whirlpool therapy
Number of subjects: 63
Study: 8038616

Group type: EXPERIMENTAL
Intervention: Albunex
Number of subjects: 34

Group type: COMPARATOR
Intervention: 5% human serum albumin (0.01 ml/kg)
Number of subjects: 34
Study: 3149929

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 105

Group type: COMPARATOR
Intervention: Cefuroxime plus Gentamicin
Number of subjects: 105
Study: 31138332

Group type: EXPERIMENTAL
Intervention: Eribulin plus gemcitabine (EG)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Paclitaxel plus gemcitabine (PG)
Number of subjects: 118
Study: 28972673

Group type: EXPERIMENTAL
Intervention: Ibandronate
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Total cohort
Number of subjects: 129
Study: 26093641

Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 2338

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2338
Study: 25208361

Group type: EXPERIMENTAL
Intervention: Gluma Desensitizer PowerGel (GLU)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: dentin burnishing with fiber‐resin burs (STB)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: MS Coat One (MSC)
Number of subjects: 61
Study: 20796082

Group type: EXPERIMENTAL
Intervention: Rice bran feed (RBF)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo feed (PF)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (CRT)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Low dose (LD)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High dose (HD)
Number of subjects: 18
Study: 19327226

Group type: EXPERIMENTAL
Intervention: Educational program intervention (6-week program, weekly sessions lasting 1 hour each)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Educational program intervention
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 58
Study: 17449497

Group type: EXPERIMENTAL
Intervention: Intravenous insulin to maintain blood glucose <10 mmol/l
Number of subjects: 43

Group type: COMPARATOR
Intervention: 200 g/day of glucose infusion (control group)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Intravenous insulin
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (200 g/day of glucose infusion)
Number of subjects: 43
Study: 14718403

Group type: EXPERIMENTAL
Intervention: Aerosolized adrenomedullin (10 microg/kg body weight)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo inhalation
Number of subjects: 11
Study: 11477965

Group type: EXPERIMENTAL
Intervention: Vi polysaccharide vaccine (30 micrograms)
Number of subjects: 131271

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 131271
Study: 9866002

Group type: EXPERIMENTAL
Intervention: Norplant
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Implanon
Number of subjects: 60
Study: 7704991

Group type: EXPERIMENTAL
Intervention: Acetylcholine (41 nmol/min) with edrophonium (0.5 mumol/min intra-arterially)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acetylcholine (16 and 41 nmol/min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acetylcholine (41 nmol/min)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methacholine (5 nmol/min)
Number of subjects: 0
Study: 2483018

Group type: COMPARATOR
Intervention: Conventional dextran alone
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Dextran with additional graded compression stockings
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Preoperative administration of dextran
Number of subjects: 150
Study: 1107969

Group type: EXPERIMENTAL
Intervention: Pizotifen
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cyproheptadine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 30694077

Group type: EXPERIMENTAL
Intervention: Oral oestradiol (4 mg/d) plus vaginal progesterone (90 mg, 2×1/day)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Vaginal progesterone (90 mg, 2×1/day) alone
Number of subjects: 150
Study: 30849606

Group type: EXPERIMENTAL
Intervention: Instability training on unstable surfaces
Number of subjects: 43

Group type: COMPARATOR
Intervention: Balance training on stable ground (Control)
Number of subjects: 43
Study: 28976605

Group type: COMPARATOR
Intervention: DHA supplementation for 16 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: DHA supplementation for 40 weeks
Number of subjects: 10
Study: 25499165

Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy (maintaining haemoglobin level at 100 g/L or higher)
Number of subjects: 2016

Group type: COMPARATOR
Intervention: Restrictive transfusion strategy (transfusion when haemoglobin level lower than 80 g/L or symptoms of anaemia)
Number of subjects: 2016
Study: 22766102

Group type: EXPERIMENTAL
Intervention: Globus pallidus deep brain stimulation (GP DBS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stimulation location within the globus pallidus
Number of subjects: 0
Study: 21247662

Group type: EXPERIMENTAL
Intervention: Aquaphor Healing Ointment (AHO)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Polysporin (Poly/Bac)
Number of subjects: 30
Study: 19592630

Group type: EXPERIMENTAL
Intervention: Insulin and metformin
Number of subjects: 58

Group type: COMPARATOR
Intervention: Metformin, pioglitazone, and glyburide (oral group)
Number of subjects: 58
Study: 17242671

Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy (platin-based chemotherapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Platin-based chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified schedules or attenuated dose of platin-containing chemotherapy
Number of subjects: 0
Study: 16422974

Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0